CBI 2026 – Antibody Drug Development Conference
Bispecific antibody deal volumes continue to hit record highs, as the battlefield for antibody therapeutics rapidly expands from oncology into multi-billion-dollar markets such as autoimmune diseases, chronic conditions, and cardiovascular disorders. From differentiated bispecific antibody development and early-stage translation strategies to CMC scale-up and commercialization, competition in the antibody drug sector has entered a new phase defined by end-to-end capabilities.
The conference features three thematic sessions: Innovation in Bispecific Antibody Drugs, Translational Strategies for Early-Stage Antibody Drug R&D, and CMC Development Strategies for Antibody Drugs. It brings together senior industry experts to engage in in-depth discussions on differentiated development, translational medicine, and industrialization. Registration is FREE!
Date: September 4–5, 2026
Location: Hall B, Booth B106, Suzhou International Expo Center, Suzhou, China
